The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

In a significant advancement for the Recessive Dystrophic Epidermolysis Bullosa (RDEB) community, the U.S. Food and Drug ...

The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis ...

The Florida Society of Clinical Oncology (FLASCO), a statewide organization dedicated to facilitating collaboration and ...

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapy for a rare genetic skin disorder.

"I wanted to create an all-natural and delicious way to consume daily vitamins and minerals," said an inventor, from El Paso, Texas, "so I invented the VITAMIN BAR. My design would serve as a ...